Back to Career Page

Science Writer

Location: United States or United Kingdom

Salary: $70 - $80K

Job Overview:

Gameto is seeking a dynamic, highly motivated candidate for the position of Science Writer to directly report to and work with the CSO and the science team of Gameto. Gameto is in a pivotal stage of development as we bring our lead product Fertilo to the global market. Fertilo is aimed at improving IVF & egg freezing processes by using iPSC-derived ovarian support cells (OSCs) to mature immature eggs outside the body, making the process shorter, safer, and more accessible. Fertilo is currently being used clinically & commercially ex-US and is preparing for an upcoming US Clinical Trial.

A successful candidate will play an important role in bridging communication, development, and coordination activities between cross-disciplinary teams of cell engineers, embryologists, and clinical partners, working closely with the CSO to streamline and advance Gameto’s research and clinical development. This candidate will lead efforts at science communication and presentation, working with the scientific team to effectively synthesize and disseminate our advances in the form of publications, abstracts, and scientific talks. Likewise, this candidate will work closely with the business development, marketing, and sales teams to more effectively communicate complex and nuanced scientific findings, outcomes, and innovations for broad audiences of clinicians, scientists, patients, and the general public.



About Gameto:

Gameto is a private biotechnology company in women’s health. Gameto is led by physician-turned-entrepreneur Dina Radenkovic as a co-founder & CEO and a serial entrepreneur & leader in the fertility space, Martin Varsavsky, founder of Prelude Network, one of the largest proprietary fertility clinics chain in the US, as Chairman.

Gameto’s underlying science platform was developed with a sponsored research agreement with Harvard University/Wyss Institute. We are using the cell engineering platform to develop novel treatment solutions for infertility and other diseases of the female reproductive system. Last year we published that our cell engineering platform of the female ovary developed with Professor George Church’s lab at Harvard Medical School surpasses the previous gold standard animal models.

Gameto has raised $40 million in a Series A from funds such as Insight Partners, Future Ventures, Lux Capital, Bold Capital, Bob Nelsen & Anne Wojcicki. Gameto currently has about $22m cash on hand. Our team is mission-driven, kind, collaborative, and authentic. Read about Gameto in MIT Technology Review, The New Yorker, The Boston Globe, and Stat News. We are an equal opportunity employer and value diversity at our company; we do not discriminate on the basis of race, religion, color, national origin, gender, sexual orientation, age, marital status, veteran status, or disability status.

If interested in this position, please apply on LinkedIn and send the following to with the email subject “Science Writer (your full name)”:

Apply Here